- Results from phase 3 studies (AD-301/302) indicate that treatment with crisaborole ointment (Eucrisa) is associated with improved QoL in patients with mild-to-moderate atopic dermatitis (AD) and their parents/caregivers/families.
Why this matters
- QoL is a major concern in treatment of AD.
- In patients, crisaborole was associated with greater mean improvement in QoL compared with vehicle (−4.6 vs −3.0 [P<.001 in children dermatology life quality index for patients aged years vs>
- Crisaborole was specifically linked with improvements in itching/scratching and painful/sore symptoms (P<.001 feelings of embarrassment and self-consciousness playing holiday time sleep burden treatment compared with vehicle.>
- In parents/caregivers/family, crisaborole was associated with greater mean improvement in QoL compared with vehicle (−3.7 vs −2.7; P=.003 in Dermatitis Family Impact).
- 1522 patients aged ≥2 years with mild-to-moderate AD, 1016 treated with crisaborole and 506 with vehicle, as well as families of patients aged 2-17 years, were analyzed for QoL.
- Funding: Anacor Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., New York, NY.
- QoL measurement tools not specific to AD.